Oral / Subcutaneous · GLP-1 agonist
Semaglutide
725 trials in this molecule. Source: ClinicalTrials.gov, as of July 6, 2026.
Trials
725
Ongoing
348
Recruiting
167
Completed
317
Sites
7,428
Countries
68
Endpoints
12,451
Composite endpoints
657
Distinct sites and countries across this molecule's trials. A site running several of its trials counts once, matching the map.
Where the program stands
Trials by phase
Early Phase 1
7
Phase 1
111
Phase 1/2
12
Phase 2
113
Phase 2/3
14
Phase 3
156
Phase 4
107
Not applicable
205
Trials by status
Not yet recruiting
103
By invitation
19
Recruiting
167
Active, not recruiting
59
Completed
317
Terminated
9
Withdrawn
12
Suspended
1
Unknown
38
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Weight & body composition
2,386
Safety / tolerability / PK
2,242
Glycemic / diabetes
2,107
Cardiometabolic biomarkers
1,875
Other clinical outcomes
998
Patient-reported / QoL
920
Other (unclassified)
834
MASH / liver
388
Cardiovascular outcomes
300
Renal / kidney
287
Heart failure
114
Top 20 metrics across this asset's endpoints
HbA1c, changeGlycemic
479
Body weight, absolute change (kg)Weight
377
Body weight, % changeWeight
315
Treatment-emergent AEs (any)Safety/PK
287
Fasting glucose, changeGlycemic
262
Waist circumference, changeWeight
259
BMI, changeWeight
204
HbA1c <7.0% achievementGlycemic
200
AUC₀-∞Safety/PK
198
Triglycerides, changeBiomarker
187
LDL-C, changeBiomarker
177
HDL-C, changeBiomarker
170
Total cholesterol, changeBiomarker
168
≥5% weight-loss respondersWeight
163
Documented hypoglycemiaSafety/PK
155
Systolic BP, changeBiomarker
152
CmaxSafety/PK
152
≥10% weight-loss respondersWeight
142
Immunogenicity (ADA)Safety/PK
137
Total fat massWeight
129
Programs for this asset
Every trial for this molecule, with the same search, filters, and sort as the Trials tab.
⌘K
725 of 725
Showing 1-25 of 725 trials